Welcome to our dedicated page for Petros Pharmaceuticals SEC filings (Ticker: PTPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Petros Pharmaceuticals, Inc. filings document its public-company reporting status, governance actions and corporate-status changes. The record includes Form 8-K disclosures on restricted stock unit grants to directors and officers, Nasdaq delisting notices, continued OTCID Basic Market trading under PTPI, and a Form 25 covering removal of the company’s common stock from Nasdaq listing and Section 12(b) registration.
Other filings address annual-report timing through a Form 12b-25 notification and operating matters tied to Metuchen Pharmaceuticals, including termination of the Stendra license arrangement and related commercialization rights. These disclosures frame the company’s capital structure, reporting obligations, incentive compensation and subsidiary-related business changes.
Boctor Fady reported acquisition or exercise transactions in this Form 4 filing.
Petros Pharmaceuticals, Inc. reported that officer Fady Boctor received a grant of 375,000 shares of common stock as equity compensation. The filing states that 50% of these restricted shares vested on the grant date, while the remaining 50% will vest after six months if he continues providing services, bringing his direct holdings to 894,986 shares.
Bernstein Bruce reported acquisition or exercise transactions in this Form 4 filing.
Petros Pharmaceuticals director Bruce Bernstein received a grant of 1,875,000 restricted shares of common stock. The shares were awarded at a price of $0.00 per share as equity compensation. After this grant, he directly holds 3,762,334 common shares.
According to the terms, 50% of the restricted shares vested on the grant date and the remaining 50% will vest on the six-month anniversary of the grant, provided he is still providing services to the company at that time.
Silverman Joshua reported acquisition or exercise transactions in this Form 4 filing.
Petros Pharmaceuticals director Joshua Silverman reported receiving a large stock award in the form of restricted common shares. He was granted 4,375,000 shares of Petros Pharmaceuticals common stock as a grant or award, rather than an open-market purchase.
According to the terms, 50% of these restricted shares vested on the grant date, while the remaining 50% will vest six months after the grant date if he is still providing services to the company at that time. Following this grant, Silverman directly holds a total of 8,790,450 shares of Petros Pharmaceuticals common stock.
Petros Pharmaceuticals, Inc. approved new equity awards for key leaders. On June 5, 2026, the Board granted an aggregate of 7,000,000 restricted shares of common stock to its chairman, two directors, and its President and Chief Commercial Officer. Joshua Silverman received 4,375,000 restricted shares, Bruce Bernstein 1,875,000, and both Fady Boctor and Wayne Walker 375,000 each. Half of each award vested immediately on the grant date, and the remaining half will vest six months later if the recipient is still providing services. These restricted share awards were issued outside the company’s Amended and Restated 2020 Omnibus Incentive Compensation Plan and are governed by a standard Restricted Stock Award Agreement.
Petros Pharmaceuticals reported a smaller loss in Q1 2026 but remains under significant financial strain. The company had no continuing revenue and recorded a net loss of $987,036, improved from $2,260,022 a year earlier, helped by lower selling, general and administrative expenses, which fell about 30% to $1,027,179. Cash used in operating activities was $784,272, leaving cash and cash equivalents of $4,352,450 and working capital of about $1.8M as of March 31, 2026. Management states the company does not have sufficient liquidity to fund operations for the next 12 months and discloses “substantial doubt” about its ability to continue as a going concern. Petros has exited its historical erectile‑dysfunction drug and device businesses and is now an early‑stage platform developer focused on Rx‑to‑OTC switch and ACNU technologies, while its common stock trades on the OTC market following delisting from Nasdaq.
Petros Pharmaceuticals, Inc. files its annual report describing a major shift from erectile dysfunction products to developing a SaaS/SaMD platform to support prescription-to-OTC switches. The 10-K highlights severe liquidity constraints, a going concern warning, and reliance on future capital raises and platform commercialization.
The company exited Stendra and VEDs, assigned related subsidiaries’ assets for the benefit of creditors, and defaulted on a Vivus promissory note, leading to foreclosure on Stendra-related collateral and termination of the Vivus license. Petros now focuses on early-stage, technology-driven Rx-to-OTC solutions without current platform revenue.
Petros Pharmaceuticals, Inc. filed a Form 12b-25 notifying the SEC it cannot timely file its Annual Report on Form 10-K for the year ended December 31, 2025 because it needs additional time to complete and finalize the required financial statements. The company anticipates filing the Form 10-K on or before the fifteenth calendar day following the prescribed due date.
Petros Pharmaceuticals, Inc. received an updated ownership report showing that Iroquois Capital Management, Richard Abbe, and Kimberly Page together beneficially own 9.99% of its common stock. This percentage reflects contractual limits that cap how much of Petros’s stock they are treated as owning at any time.
The group’s position includes 2,380,394 shares of common stock held by Iroquois Master Fund, 34,512 shares held by Iroquois Capital Investment Group, and 2,019,867 additional shares issuable from warrants and preferred stock after applying these ownership caps. Petros had 42,372,260 shares outstanding as of November 12, 2025.
Petros Pharmaceuticals, Inc. reported an equity grant to one of its senior executives. Officer Fady Boctor, who serves as President & Chief Commercial Officer, received 500,000 restricted stock units (RSUs) of Petros common stock on 01/02/2026 at a stated price of $0 per unit.
According to the terms, 50% of these RSUs vested on the grant date, and the remaining 50% will vest on the six‑month anniversary of the grant date if he is still providing services to the company. Each RSU gives the right to receive one share of common stock. After this grant, Boctor beneficially owned 519,986 shares of Petros common stock, with amounts adjusted for the company’s 1‑for‑25 reverse stock split that became effective at 4:05 p.m. New York time on April 30, 2025.
Petros Pharmaceuticals, Inc. director Joshua Silverman reported a new equity award in the company’s common stock. On 01/02/2026, he received 4,375,000 restricted stock units (RSUs) at a price of $0, reflecting a compensatory grant. Half of these RSUs vested on the grant date, and the remaining half will vest on the six‑month anniversary of the grant, provided he continues providing services to the company.
Each RSU represents the right to receive one share of common stock with a par value of $0.0001 per share. Following this transaction, Silverman beneficially owned 4,415,450 shares of Petros Pharmaceuticals common stock directly. The reported amounts have been adjusted to reflect the company’s 1‑for‑25 reverse stock split of its common stock that became effective at 4:05 p.m. New York time on April 30, 2025.